Today: 11 June 2026
Wells Fargo stock slips as credit-card rate cap deadline hits — what could move WFC next
20 January 2026
2 mins read

Wells Fargo stock slips as credit-card rate cap deadline hits — what could move WFC next

New York, Jan 20, 2026, 12:28 EST — Regular session

  • Wells Fargo shares slipped alongside other U.S. bank stocks as the deadline for Washington’s credit-card rate cap hit.
  • Investors are debating whether a 10% cap can be enforced at all without congressional approval
  • Up next: any guidance released after the close and the Federal Reserve’s meeting scheduled for next week

Wells Fargo & Co shares dropped 0.6% to $87.84 in midday trading Tuesday as U.S. bank stocks fell ahead of a Trump administration deadline linked to a proposed 10% cap on credit card interest rates. The S&P 500 Banks index slid 1.2%, while JPMorgan Chase and Citigroup declined 1.8% and 2.4%, respectively.

The policy threat hits a lucrative slice of consumer banking: interest from card balances. U.S. Bancorp CEO Gunjan Kedia cautioned that “90 plus percent” of its customers would suffer if a broad cap is imposed. KBW managing director Sanjay Sakhrani added that a negotiated compromise seems “the only somewhat viable option.” Reuters

Bank lobbyists fired back hard. The American Bankers Association pointed to fresh data from issuers representing about 75% of the market, showing that a 10% cap could force 74%–85% of open credit card accounts to close or see their credit lines slashed. That would leave up to 159 million cardholders unable to use their cards. “Interest rate caps lead to fewer options,” ABA chief executive Rob Nichols said. American Bankers Association

Citigroup CEO Jane Fraser said she doubts Congress will approve an interest-rate cap, cautioning it could limit credit availability and impact sectors that depend on card spending. “Capping rates would not be good for the U.S. economy,” Fraser told CNBC during an interview at Davos. Reuters

The scene remains unsettled. On Tuesday, the Cboe Volatility Index — Wall Street’s so-called “fear gauge” derived from options pricing — hit its highest point in eight weeks amid renewed tariff threats targeting Europe. The S&P 500 slipped roughly 1%. Reuters

Wells Fargo now faces a pressing question: will the administration deliver enforcement or just the mechanics after hours? A strict cap on unsecured credit would pinch pricing, potentially pushing lenders to cut rewards, raise fees, or tighten limits to safeguard profits.

The road ahead is anything but smooth. Executives and analysts caution that a blunt cap might backfire, tightening credit for borrowers. Banks have even suggested they might challenge any unilateral action in court. Should Washington pull back or opt for voluntary low-rate offerings, the sector could stabilize quickly.

Traders are watching rates closely ahead of the Federal Reserve’s policy meeting set for Jan. 27-28. Bank stocks often react to changes in expectations around borrowing costs and credit demand.

Treasury Secretary Scott Bessent said President Donald Trump might choose the next Fed chair as soon as next week, a move markets will watch closely for clues on future rate policy. “My guess is that the president will reach a decision, maybe as soon as next week,” Bessent told CNBC. Reuters

Wells Fargo investors are focused this afternoon on two key points: whether the White House will weigh in on the credit-card cap following Tuesday’s deadline, and what next week’s Fed meeting might reveal about the duration of this policy-driven volatility.

Stock Market Today

  • Valion Bio Gains U.S. House Armed Services Committee Support for Radiation Countermeasures
    June 11, 2026, 8:12 AM EDT. Valion Bio (NASDAQ: VBIO) confirmed that the U.S. House Armed Services Committee's FY27 National Defense Authorization Act prioritizes radiation/nuclear countermeasures with both prophylactic (pre-exposure) and therapeutic (post-exposure) effects. This follows Valion Bio's briefings to senior Department of War officials and BARDA on its lead candidate Entolimod, a biologic designed to protect and mitigate acute radiation syndrome. Entolimod showed survival benefits in primate studies under FDA regulatory guidelines. CEO Michael Handley praised the Committee's recognition of the need for preventive radiation agents, highlighting increased U.S. defense focus on enhanced nuclear preparedness and response capabilities.

Latest articles

CCH Holdings (CCHH) jumps with Nasdaq $1 bid rule deadline close

CCH Holdings (CCHH) jumps with Nasdaq $1 bid rule deadline close

11 June 2026
CCH Holdings soared 136.99% to $0.82 in premarket trading after being flagged as a top U.S. mover, pulling the Malaysian hotpot chain closer to Nasdaq’s $1 minimum bid requirement ahead of its August 3 deadline, despite no new earnings or business catalyst and recent financial losses, raising questions about the rally’s sustainability.
SpaceX IPO: SPCX $135 Listing Meets $250 Billion Demand

SpaceX IPO: SPCX $135 Listing Meets $250 Billion Demand

11 June 2026
SpaceX’s $75 billion IPO is over three times oversubscribed with $250 billion in investor demand, setting a $135-a-share price for a potential $1.75 trillion valuation, but 2025’s $4.94 billion net loss and a 94x price-to-sales ratio highlight risks as investors weigh Starlink growth against heavy AI and rocket spending.
Grab stock rises even as Wall Street slides after BofA upgrade — what’s next for GRAB
Previous Story

Grab stock rises even as Wall Street slides after BofA upgrade — what’s next for GRAB

Dow Jones today: Dow drops 870 points on Trump Greenland tariff threat as volatility jumps
Next Story

Dow Jones today: Dow drops 870 points on Trump Greenland tariff threat as volatility jumps

Go toTop